Spend a summer in Washington, DC
Live in the nation’s capitol working on policy and advocacy issues for the bleeding disorder community.
About the internship
Spend 10 weeks in Washington, DC as our Policy & Government Relations intern from May 31 to August 4, 2023. HFA will provide leadership, guidance, housing, and a stipend for two college students or recent graduates with bleeding disorders or students related to a person with a bleeding disorder.
Interns will conduct research and analysis to help create educational resources on a variety of issue areas related to bleeding disorders. Other responsibilities may include attending relevant in-person and virtual events, providing support for webinars, assisting with Public Affairs’ programs, and drafting bi-weekly blog posts. A typical schedule for a Policy & Government Relations intern will be to work from Monday to Thursday (roughly 30-35 hours a week).
Ultimately, we seek to further develop a core passion in health care policy and self-advocacy, helping to shape the next generation of advocacy leaders.
Deadline to apply: March 3, 2023
Requirements
- Must be available for ten (10) weeks.
- Must be currently enrolled in (or just previously graduated from) college.
- Must be of or over the age of 18.
- Must have a bleeding disorder or be related to a person with a bleeding disorder.
- Must have a demonstrable interest in policy, government relations, and/or advocacy work, including but not limited to prior experience or pursuing a degree in political science or related field of study.
- Must have excellent oral communication, writing, and research skills.
- Attend and participate in July's Young Adult Advocacy Summit.
About HFA
Hemophilia Federation of America is a national 501(c)(3) organization consisting of more than 50 member organizations and numerous individual members who offer assistance and grassroots advocacy education on behalf of the bleeding disorders community. Incorporated in 1994, the HFA provides programs and services to improve the quality of life for persons with hemophilia, von Willebrand disease (VWD) and other rare bleeding disorders.